AstraZeneca: vaccine efficacy downgraded
(CercleFinance.com) - AstraZeneca announced on Thursday that its Covid-19 vaccine achieved an efficacy rate of 76% in phase III clinical trials, down from the previously reported 79%.
The biopharmaceutical group explained that its vaccine prevented symptomatic forms of the disease in 76% of the patients monitored, a rate that rose to 85% in those over 65.
AstraZeneca announced on Monday that its vaccine against Covid had shown 79% effectiveness in preventing symptomatic forms of the disease in this clinical trial conducted in the United States.
The laboratory justifies this downward revision by the occurrence of 49 additional symptomatic cases of Covid in its study, which brings their total number to 190, for a total of 32,449 participants.
Based on these results, AstraZeneca said it plans to file a marketing application for its vaccine in the US in the near future, saying that it is ready to deliver several million doses to the country.
Following these announcements, the share rose still timidly rose 0.3% on Thursday morning on the London Stock Exchange. However, the stock has lost more than 11% over the past three months due to the many controversies, suspensions and the like surrounding its vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
The biopharmaceutical group explained that its vaccine prevented symptomatic forms of the disease in 76% of the patients monitored, a rate that rose to 85% in those over 65.
AstraZeneca announced on Monday that its vaccine against Covid had shown 79% effectiveness in preventing symptomatic forms of the disease in this clinical trial conducted in the United States.
The laboratory justifies this downward revision by the occurrence of 49 additional symptomatic cases of Covid in its study, which brings their total number to 190, for a total of 32,449 participants.
Based on these results, AstraZeneca said it plans to file a marketing application for its vaccine in the US in the near future, saying that it is ready to deliver several million doses to the country.
Following these announcements, the share rose still timidly rose 0.3% on Thursday morning on the London Stock Exchange. However, the stock has lost more than 11% over the past three months due to the many controversies, suspensions and the like surrounding its vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.